(Q36915178)

17 August 2017

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome (English)

1 reference

17 August 2017

12

Hagop M Kantarjian

1 reference

17 August 2017

1

Stefan Faderl

1 reference

17 August 2017

3

Zeev Estrov

1 reference

17 August 2017

7

Susan O'Brien

1 reference

17 August 2017

4

Farhad Ravandi

1 reference

17 August 2017

5

Gautam Borthakur

1 reference

17 August 2017

Guillermo Garcia-Manero

series ordinal

2

object named as

Guillermo Garcia-Manero

1 reference

17 August 2017

6

Jorge E Cortes

1 reference

17 August 2017

9

William Plunkett

1 reference

17 August 2017

11

Monica Kwari

1 reference

17 August 2017

Varsha Gandhi

8

1 reference

17 August 2017

Anna Byrd

series ordinal

10

1 reference

17 August 2017

language of work or name

English

0 references

publication date

26 April 2010

1 reference

Journal of Clinical Oncology

17 August 2017

1 reference

17 August 2017

28

1 reference

17 August 2017

16

1 reference

17 August 2017

2755-2760

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Clofarabine: past, present, and future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Myelodysplasic syndromes: a comprehensive review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

The World Health Organization (WHO) classification of the myeloid neoplasms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

International scoring system for evaluating prognosis in myelodysplastic syndromes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4872315

Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20421540

12 December 2020

inferred from PubMed ID database lookup

Predicting survival and leukemic evolution in patients with myelodysplastic syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20421540

12 December 2020

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20421540

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.2009.26.3509

1 reference

release_b5r2fljk7zbsfmalt6vcyyyu4u

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b5r2fljk7zbsfmalt6vcyyyu4u

24 November 2022

mapped directly with Wikidata item

1 reference

17 August 2017

PubMed publication ID

20421540

1 reference